Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend up since Sep 2 · below the Ichimoku cloud · RSI 41 · MACD below its signal · 1% below its 52-week high
None of the 29 investors followed here reported a position in OACC in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a OACC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for OACC.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.7 | 0.5 | -1.1 | 0.3 | 0.7 | 0.2 | 0.4 | 0.2 | 0.2 | -0.3 | +1.6% | ||
| 2025 | 0.0 | 0.8 | 1.9 | 1.3 | 0.9 | 0.0 | 0.2 | -0.1 | 0.5 | 0.7 | -0.2 | 0.2 | +6.2% |
| 2024 | — |
No analyst coverage for this instrument.
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered in Los Angeles, California.
No recent headlines.